Lobe Sciences Secures European Patent Protection for DHA-Based Sickle Cell Disease Treatment
Key Insights
Lobe Sciences has obtained European Unitary Patent EP4117446 validation, providing intellectual property protection across 17 EU member states for its DHA and egg yolk-based composition targeting Sickle Cell Disease (search).
The patent covers the formulation underlying Altemia (search)® Medical Food, a first-in-class emulsified oral treatment designed to restore red blood cell membrane (search) integrity and address long-chain fatty acid deficiencies in SCD patients.
This validation strengthens Lobe's intellectual property portfolio and enables broader commercialization of Altemia (search)® across key European markets as part of the company's global expansion strategy.
Lobe Sciences Ltd. has achieved a significant regulatory milestone with the European Patent Office (search)'s validation of European Patent EP4117446 as a Unitary Patent, securing intellectual property protection for its innovative DHA-based composition targeting Sickle Cell Disease (search) (SCD) across 17 European Union member states.
Patent Coverage and Geographic Scope
The validated patent, titled "A Composition Comprising Docosahexaenoic Acid… for Sickle Cell Disease (search) Treatment," provides protection across Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Portugal, Romania, Sweden, and Slovenia. The patent covers novel formulations combining DHA and ingredients specifically designed to address fatty acid deficiencies and related complications in SCD patients.
Altemia® Medical Food Platform
The patented composition forms the foundation of Altemia (search)® Medical Food, a first-in-class emulsified oral formulation developed to restore red blood cell membrane (search) integrity in patients with SCD. The formula leverages DHA and natural emulsifiers to improve bioavailability and effectiveness in managing long-chain fatty acid deficiencies, which represent a hallmark of SCD pathology.
Altemia (search)® is positioned as a physician-supervised medical food specifically formulated to address the nutritional deficiencies commonly observed in SCD patients, representing a novel approach to managing this complex hematologic disorder.
Strategic Implications for Global Expansion
"With this Unitary Patent in place, we are better positioned to protect and expand the reach of our proprietary SCD treatment technology throughout Europe," said Dr. Fred D. Sancilio, CEO of Lobe Sciences. "This is an important step as we continue our mission to deliver nutritional and therapeutic innovations for patients with rare and neglected diseases."
The validation marks a significant milestone in Lobe's efforts to broaden the global footprint of its SCD treatment platform and strengthens the company's intellectual property portfolio for broader commercialization across key European markets.
Company Pipeline and Focus Areas
Lobe Sciences operates as a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia, Inc. (search), and its majority-owned subsidiary, Cynaptec Pharmaceuticals, Inc. (search), the company is advancing a patented lipid-based platform for treating Sickle Cell Disease (search) alongside a novel oral analog of psilocin-Conjugated Psilocin (search)™-targeted at Chronic Cluster Headache (search) and other neurological disorders.
These programs are designed to address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations, reflecting the company's commitment to developing treatments for underserved diseases.